Skip to main content
OpenTrials
Completed

NCT Number: NCT02793167

Clinical Values of Automated Electronic Alert for Acute Kidney Injury

Acute kidney injury (AKI) is common, serious and expensive.It is associated with significant mortality, morbidity and increased length of hospital stay.To improve clinical outcomes of AKI by early detection and timely referral to the renal,the investigators developed an electronic alert system which identifies all cases of AKI occurring in patients over 18 years.The system was also designed to collect data on AKI incidence one of the biggest tertiary hospital in China.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Kidney Injury Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Kidney Diseases Male Urogenital Diseases Renal Insufficiency Urogenital Diseases Urologic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nephrology Dept,Guangdong General Hospital

Guangzhou, Guangdong, China

About this study

A prospective, randomly controlled cohort study will be conducted agmong the patients with AKI who are detected by the use of AKI sniffer. The investigators chose to assess all inpatient serum creatinine results using a combination of "KDIGO" criteria.

The investigators randomly divided the patients into two groups:

  • Usual care : patients will receive standard clinical care by the primary physicians
  • AKI alert : an AKI alert will be sent to the the doctor in charge. Our team of kidney experts would give a suggestion if the the doctor in charge issue consultation applications.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult patients with an Alert for AKI(based on KDIGO guidelines)

Exclusion criteria

  • patients already on dialysis for AKI at the time of alert
  • patients with End stage renal disease
  • patients <18 years of age
  • patients dissenting from participation according to the Ethics application

Treatment and study plan

AKI alert

Device

Primary outcomes

  1. Adverse events during hospitalization

    Time frame: from start of AKI to discharge,up to 4 weeks

    cardiac shock/ need for intensive care/ cardiopulmonary resuscitation/ cardiac death/ death

  2. Incidence of cardiovascular disease and its occurrence time followed up for 1 years

    Time frame: One year after discharge

    heart failure/ acute coronary syndrome/ readmission/cardiac readmission/ cardiovascular intervention or surgery

  3. The AKI outcome and its occurrence time followed up for 1 years

    Time frame: One year after discharge

    AKI recovery/stop renal replacement therapy

  4. AKI recovery/stop renal replacement therapy

    Time frame: from start of AKI to discharge,up to 4 weeks

    Glomerular filtration rate decreased/ new occurrence proteinuria/ original proteinuria aggravation

Secondary outcomes

  1. Proportion of nephrology referral

    Time frame: from start of AKI to discharge,up to 4 weeks

  2. Diagnostic rate of AKI at discharge

    Time frame: from start of AKI to discharge,up to 4 weeks

  3. Follow-up rate after discharge

    Time frame: One year after discharge

Sponsors and collaborators

Lead sponsor

XinLing Liang

Other

Registry information

Official study title

Clinical Values of Automated Electronic Alert for Acute Kidney injury-a Prospective ,Randomly Controlled Cohort Study

Important dates

Study start
2016
Primary completion
2021
Study completion
2022
First posted
Jun 8, 2016
Registry last updated
Feb 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.